55.21
price up icon5.58%   2.92
after-market After Hours: 55.21
loading
Rhythm Pharmaceuticals Inc stock is traded at $55.21, with a volume of 685.47K. It is up +5.58% in the last 24 hours and down -4.81% over the past month. Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
See More
Previous Close:
$52.29
Open:
$52.25
24h Volume:
685.47K
Relative Volume:
1.40
Market Cap:
$3.49B
Revenue:
$112.53M
Net Income/Loss:
$-258.91M
P/E Ratio:
-12.75
EPS:
-4.33
Net Cash Flow:
$-124.42M
1W Performance:
+7.58%
1M Performance:
-4.81%
6M Performance:
+1.21%
1Y Performance:
+41.13%
1-Day Range:
Value
$52.15
$55.87
1-Week Range:
Value
$50.13
$55.87
52-Week Range:
Value
$35.17
$68.58

Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile

Name
Name
Rhythm Pharmaceuticals Inc
Name
Phone
857-264-4280
Name
Address
222 BERKELEY STREET, BOSTON, MA
Name
Employee
283
Name
Twitter
@rhythmpharma
Name
Next Earnings Date
2024-11-05
Name
Latest SEC Filings
Name
RYTM's Discussions on Twitter

Compare RYTM with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
RYTM
Rhythm Pharmaceuticals Inc
55.21 3.49B 112.53M -258.91M -124.42M -4.33
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
512.52 131.61B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
672.36 73.51B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
619.97 37.67B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
253.44 32.81B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
266.26 28.62B 3.81B -644.79M -669.77M -6.24

Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-05-25 Resumed Stifel Buy
Jan-02-25 Initiated Jefferies Buy
Dec-20-24 Initiated Oppenheimer Outperform
Oct-21-24 Initiated Guggenheim Buy
Sep-18-24 Initiated H.C. Wainwright Buy
Sep-17-24 Initiated JMP Securities Mkt Outperform
May-08-24 Downgrade BofA Securities Buy → Neutral
Dec-19-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Aug-01-23 Upgrade BofA Securities Neutral → Buy
Jan-18-23 Resumed Canaccord Genuity Buy
Aug-08-22 Upgrade Goldman Neutral → Buy
Aug-05-22 Upgrade BofA Securities Underperform → Neutral
Jun-17-22 Reiterated Needham Buy
Mar-02-22 Resumed Stifel Buy
Feb-17-22 Upgrade Ladenburg Thalmann Neutral → Buy
Dec-08-21 Initiated Wells Fargo Overweight
Nov-19-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-14-21 Resumed Goldman Neutral
Aug-04-21 Downgrade BofA Securities Neutral → Underperform
Aug-04-21 Downgrade Ladenburg Thalmann Buy → Neutral
Nov-30-20 Downgrade BofA Securities Buy → Neutral
Jan-08-20 Initiated Goldman Sell
Jul-12-19 Upgrade Stifel Hold → Buy
Jul-08-19 Initiated Canaccord Genuity Buy
Mar-13-19 Initiated Ladenburg Thalmann Buy
Sep-07-18 Resumed Morgan Stanley Overweight
Jun-25-18 Reiterated Needham Buy
Jun-15-18 Reiterated Needham Buy
Oct-30-17 Initiated BofA/Merrill Buy
Oct-30-17 Initiated Needham Buy
View All

Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News

pulisher
04:58 AM

Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted To Setmelanotide For Treatment Of Hypothalamic Obesity In Japan - Marketscreener.com

04:58 AM
pulisher
04:46 AM

Rhythm Pharmaceuticals receives orphan drug status in Japan - Investing.com

04:46 AM
pulisher
04:20 AM

Rhythm Pharmaceuticals Receives Orphan-Drug Designation in Japan for Obesity Treatment - MarketWatch

04:20 AM
pulisher
04:03 AM

Rhythm Pharmaceuticals Announces Orphan Drug Designation - GlobeNewswire

04:03 AM
pulisher
04:01 AM

Breakthrough for Rare Obesity: Rhythm's Drug Wins Special Status in Japan - StockTitan

04:01 AM
pulisher
03:26 AM

Charles Schwab Investment Management Inc. Has $24.65 Million Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World

03:26 AM
pulisher
02:50 AM

Rhythm Pharmaceuticals (NASDAQ:RYTM) Given New $66.00 Price Target at Needham & Company LLC - Defense World

02:50 AM
pulisher
Mar 18, 2025

Rhythm Pharmaceuticals EVP sells shares worth $3.86 million - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

Needham raises Rhythm Pharma stock target to $66, maintains buy By Investing.com - Investing.com UK

Mar 18, 2025
pulisher
Mar 18, 2025

Rhythm Pharmaceuticals and Raymond A. Wood Foundation Launch Research Collaboration on Fatigue in Craniopharyngioma Patients - Nasdaq

Mar 18, 2025
pulisher
Mar 18, 2025

Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration - GlobeNewswire

Mar 18, 2025
pulisher
Mar 18, 2025

Major Breakthrough: Rhythm Pharma's New Research Tackles Devastating Fatigue in Brain Tumor Patients - StockTitan

Mar 18, 2025
pulisher
Mar 15, 2025

Bank of New York Mellon Corp Sells 680 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World

Mar 15, 2025
pulisher
Mar 14, 2025

Insider Sell Alert: EVP, Head of North America Jennifer Lee Sells Shares of Rhythm Pharmaceuticals Inc (RYTM) - GuruFocus.com

Mar 14, 2025
pulisher
Mar 12, 2025

How To Trade (RYTM) - Stock Traders Daily

Mar 12, 2025
pulisher
Mar 12, 2025

SBI Securities Co. Ltd. Invests $37,000 in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

Stifel maintains Buy on Rhythm Pharmaceuticals, $78 target By Investing.com - Investing.com Canada

Mar 12, 2025
pulisher
Mar 12, 2025

Stifel maintains Buy on Rhythm Pharmaceuticals, $78 target - Investing.com India

Mar 12, 2025
pulisher
Mar 10, 2025

Reviewing Wave Life Sciences (NASDAQ:WVE) & Rhythm Pharmaceuticals (NASDAQ:RYTM) - Defense World

Mar 10, 2025
pulisher
Mar 09, 2025

Rhythm Pharmaceuticals (NASDAQ:RYTM) Earns Overweight Rating from Morgan Stanley - Defense World

Mar 09, 2025
pulisher
Mar 07, 2025

Assessing Rhythm Pharmaceuticals: Insights From 10 Financial Analysts - Benzinga

Mar 07, 2025
pulisher
Mar 07, 2025

Promising Outlook for Rhythm Pharmaceuticals: Buy Rating Backed by Positive Phase 3 Study Expectations and Market Potential - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

Stifel Nicolaus Begins Coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

Analysts Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) PT at $68.27 - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

HC Wainwright Brokers Raise Earnings Estimates for RYTM - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

Citizens JMP maintains Rhythm Pharma Outperform, $81 target By Investing.com - Investing.com South Africa

Mar 07, 2025
pulisher
Mar 06, 2025

Citizens JMP maintains Rhythm Pharma Outperform, $81 target - Investing.com India

Mar 06, 2025
pulisher
Mar 06, 2025

Principal Financial Group Inc. Purchases 4,298 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World

Mar 06, 2025
pulisher
Mar 06, 2025

Brokers Issue Forecasts for RYTM FY2026 Earnings - Defense World

Mar 06, 2025
pulisher
Mar 06, 2025

Promising Market Potential for Rhythm Pharmaceuticals’ Setmelanotide in Treating Hypothalamic Obesity - TipRanks

Mar 06, 2025
pulisher
Mar 05, 2025

Stifel raises Rhythm Pharmaceuticals stock to Buy with $78 target By Investing.com - Investing.com Canada

Mar 05, 2025
pulisher
Mar 05, 2025

US High Growth Tech Stocks to Watch in March 2025 - Yahoo Finance

Mar 05, 2025
pulisher
Mar 04, 2025

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates - MSN

Mar 04, 2025
pulisher
Mar 04, 2025

Y Intercept Hong Kong Ltd Invests $328,000 in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World

Mar 04, 2025
pulisher
Mar 04, 2025

HC Wainwright Issues Positive Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

Rhythm Pharmaceuticals Faces Financial Risks Due to Convertible Preferred Stock Prioritization - MSN

Mar 03, 2025
pulisher
Mar 03, 2025

Rhythm Pharmaceuticals stock target raised to $70 at H.C. Wainwright - Investing.com India

Mar 03, 2025
pulisher
Mar 01, 2025

Learn to Evaluate (RYTM) using the Charts - Stock Traders Daily

Mar 01, 2025
pulisher
Mar 01, 2025

Decoding Rhythm Pharmaceuticals Inc (RYTM): A Strategic SWOT Ins - GuruFocus.com

Mar 01, 2025
pulisher
Mar 01, 2025

Needham & Company LLC Reaffirms “Buy” Rating for Rhythm Pharmaceuticals (NASDAQ:RYTM) - Defense World

Mar 01, 2025
pulisher
Mar 01, 2025

Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - Defense World

Mar 01, 2025
pulisher
Feb 28, 2025

Rhythm Pharmaceuticals (NASDAQ:RYTM) Posts Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $81.00 - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Rhythm Pharmaceuticals sets annual meeting for June 24 By Investing.com - Investing.com South Africa

Feb 28, 2025
pulisher
Feb 28, 2025

Rhythm Pharmaceuticals sets annual meeting for June 24 - Investing.com

Feb 28, 2025
pulisher
Feb 28, 2025

Rhythm Pharmaceuticals (NASDAQ:RYTM) Earns Buy Rating from Needham & Company LLC - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

RHYTHM PHARMACEUTICALS, INC. SEC 10-K Report - TradingView

Feb 28, 2025
pulisher
Feb 28, 2025

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Purchased by Rhumbline Advisers - Defense World

Feb 28, 2025
pulisher
Feb 27, 2025

Rhythm Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Citizens JMP raises Rhythm Pharma stock target to $81 By Investing.com - Investing.com Canada

Feb 27, 2025
pulisher
Feb 27, 2025

State of New Jersey Common Pension Fund D Makes New Investment in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat

Feb 27, 2025

Rhythm Pharmaceuticals Inc Stock (RYTM) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$78.94
price up icon 2.53%
$318.85
price up icon 1.51%
$33.41
price up icon 0.00%
$20.11
price up icon 1.41%
$99.27
price up icon 0.31%
biotechnology ONC
$266.26
price up icon 1.87%
Cap:     |  Volume (24h):